brodalumab
Sign in to saveAlso known as Siliq
Brodalumab, sold under the brand name Siliq in the US and Kyntheum in the EU, is a human monoclonal antibody designed for the treatment of inflammatory diseases.
Research
739 papers- Brodalumab.2006
- Secukinumab, ixekizumab, bimekizumab and brodalumab for psoriasis and psoriatic arthritis.Drugs of today (Barcelona, Spain : 1998) · 2023
- Brodalumab.2012
- Brodalumab: A Review of Safety.Skin therapy letter · 2018
- Brodalumab for the treatment of plaque psoriasis: up-to-date.Expert opinion on biological therapy · 2019
via PubMed
Wikidata facts
- Subclass of
- chemical compound
- Has use
- medication
Show 5 more facts
- medical condition treated
- psoriasis
- World Health Organisation international non-proprietary name
- brodalumabum
- subject has role
- monoclonal antibody
- defined daily dose
- 15
- legal status (medicine)
- boxed warning
via Wikidata · CC0
~2 min read
Encyclopedic overview
3 sectionsContents
- Mechanism of action
- History
- References
Brodalumab, sold under the brand name Siliq in the US and Kyntheum in the EU, is a human monoclonal antibody designed for the treatment of inflammatory diseases.
In February 2017, it received US FDA approval to treat moderate to severe plaque psoriasis in people who have not improved with other treatments.
Excerpted from Wikipedia’s “brodalumab” article, available under the CC BY-SA 4.0 licence.